Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease.

Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I.

Mov Disord. 2012 Sep 15;27(11):1392-7. doi: 10.1002/mds.25157. Epub 2012 Sep 13.

2.

Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients.

Santangelo G, Vitale C, Picillo M, Cuoco S, Moccia M, Pezzella D, Erro R, Longo K, Vicidomini C, Pellecchia MT, Amboni M, Brunetti A, Salvatore M, Barone P, Pappatà S.

Parkinsonism Relat Disord. 2015 May;21(5):489-93. doi: 10.1016/j.parkreldis.2015.02.015. Epub 2015 Feb 25.

PMID:
25753457
3.
4.

Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.

Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, van Dyck CH, Innis RB.

J Nucl Med. 1998 Sep;39(9):1500-8.

5.

Application of texture analysis to DAT SPECT imaging: Relationship to clinical assessments.

Rahmim A, Salimpour Y, Jain S, Blinder SA, Klyuzhin IS, Smith GS, Mari Z, Sossi V.

Neuroimage Clin. 2016 Feb 23;12:e1-e9. eCollection 2016.

6.

[[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy.

Berding G, Brücke T, Odin P, Brooks DJ, Kolbe H, Gielow P, Harke H, Knoop BO, Dengler R, Knapp WH.

Nuklearmedizin. 2003 Feb;42(1):31-8.

PMID:
12601452
7.

Early-stage [123I]beta-CIT SPECT and long-term clinical follow-up in patients with an initial diagnosis of Parkinson's disease.

Stoffers D, Booij J, Bosscher L, Winogrodzka A, Wolters EC, Berendse HW.

Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):689-95. Epub 2005 Jan 29.

PMID:
15682332
8.
10.

Survival in Parkinson's disease in relation to striatal dopamine transporter binding.

Mäkinen E, Joutsa J, Vahlberg T, Kaasinen V.

Parkinsonism Relat Disord. 2017 Sep;42:66-72. doi: 10.1016/j.parkreldis.2017.06.013. Epub 2017 Jun 23.

PMID:
28662820
11.

Functional morphometry of the striatum in Parkinson's disease on three-dimensional surface display of 123I-beta-CIT SPECT data.

Ichise M, Kim YJ, Erami SS, Ballinger JR, Vines D, Tanaka F, Lang AE.

J Nucl Med. 1999 Apr;40(4):530-8.

12.

Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.

Seibyl JP, Marek K, Sheff K, Baldwin RM, Zoghbi S, Zea-Ponce Y, Charney DS, van Dyck CH, Hoffer PB, Innis RB.

J Nucl Med. 1997 Sep;38(9):1453-9.

13.
14.

Ventral striatal dopaminergic defect is associated with hallucinations in Parkinson's disease.

Jaakkola E, Joutsa J, Mäkinen E, Johansson J, Kaasinen V.

Eur J Neurol. 2017 Nov;24(11):1341-1347. doi: 10.1111/ene.13390. Epub 2017 Aug 22.

PMID:
28834102
15.

Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123I-beta-CIT SPECT.

Kim SE, Choi JY, Choe YS, Choi Y, Lee WY.

J Nucl Med. 2003 Jun;44(6):870-6.

16.

Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease.

Scherfler C, Seppi K, Donnemiller E, Goebel G, Brenneis C, Virgolini I, Wenning GK, Poewe W.

Brain. 2005 Jul;128(Pt 7):1605-12. Epub 2005 Apr 7.

PMID:
15817519
17.

SPECT imaging of the dopamine transporter with [(123)I]-beta-CIT reveals marked decline of nigrostriatal dopaminergic function in Parkinson's disease with urinary dysfunction.

Sakakibara R, Shinotoh H, Uchiyama T, Yoshiyama M, Hattori T, Yamanishi T.

J Neurol Sci. 2001 Jun 15;187(1-2):55-9.

PMID:
11440745
18.

Drug-naive patients with Parkinson's disease in Hoehn and Yahr stages I and II show a bilateral decrease in striatal dopamine transporters as revealed by [123I]beta-CIT SPECT.

Tissingh G, Bergmans P, Booij J, Winogrodzka A, van Royen EA, Stoof JC, Wolters EC.

J Neurol. 1998 Jan;245(1):14-20.

PMID:
9457623
19.
20.

Prospective clinical and DaT-SPECT imaging in premotor LRRK2 G2019S-associated Parkinson disease.

Sierra M, Martínez-Rodríguez I, Sánchez-Juan P, González-Aramburu I, Jiménez-Alonso M, Sánchez-Rodríguez A, Berciano J, Banzo I, Infante J.

Neurology. 2017 Aug 1;89(5):439-444. doi: 10.1212/WNL.0000000000004185. Epub 2017 Jul 5.

Supplemental Content

Support Center